AXL Receptor Inhibition for Preeclampsia Treatment ID: 2016-022
An innovative approach to treating preeclampsia by inhibiting AXL receptor signaling, offering potential for improved pregnancy outcomes.
Technology Overview
The technology involves the use of AXL receptor inhibitors, specifically R428, to counteract the effects of Growth arrest-specific 6 (Gas6) in the development of preeclampsia (PE). This condition, a significant cause of preterm birth globally, is characterized by elevated blood pressure and proteinuria. The research demonstrated that Gas6, through its interaction with AXL receptors, plays a crucial role in the pathogenesis of PE. By inhibiting this pathway, the study showed a reversal of preeclampsia symptoms in animal models, positioning AXL receptor inhibition as a promising therapeutic strategy.
Key Advantages
- Targets the underlying pathogenic mechanisms of preeclampsia
- Potentially reduces the global incidence of preterm births associated with PERepresents a novel application of AXL inhibition, previously researched in cancer therapy
- Offers a non-invasive treatment option compared to current preeclampsia management strategies
Problems Addressed
- High blood pressure and proteinuria in preeclampsia patients
- Shallow invasion of trophoblast cells
- Increased placental apoptosis associated with PELack of targeted therapies for preeclampsia
Additional Information
Technology ID: 2016-022
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report